Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sprott Physical Gold and Silver Trust (CEF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
16.68-0.14 (-0.83%)
At close: 04:00PM EDT
16.72 +0.05 (+0.27%)
After hours: 04:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.82
Open16.53
Bid16.62 x 900
Ask17.54 x 1300
Day's Range16.48 - 16.73
52 Week Range16.48 - 20.44
Volume551,729
Avg. Volume590,719
Market Cap3.678B
Beta (5Y Monthly)-0.08
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 30, 2017
1y Target EstN/A
  • GlobeNewswire

    Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations

    Ms. Dolphin is a key strategic addition to the team, and will have an impact on the corporate strategy and growth opportunities of the companyVANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by

  • GlobeNewswire

    Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive®) Supplementation in treating OA

    VANCOUVER, British Columbia, June 17, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that a clinical study conducted by its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has shown positive res

Advertisement
Advertisement